Edesa Biotech, Inc. (EDSA)
Chart Events
Performance Outlook
| Previous Close | 1.0400 |
| Open | 1.0400 |
| Bid | 1.0200 x 800 |
| Ask | 1.0500 x 900 |
| Day's Range | 1.0100 - 1.0800 |
| 52 Week Range | 0.7600 - 3.5300 |
| Volume | |
| Avg. Volume | 374,562 |
| Market Cap | 20.031M |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1050 |
| Earnings Date | May 11, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- ACCESSWIRE
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD) annual meeting being held March 17-21, 2023.
- ACCESSWIRE
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company and the U.S. Food and Drug Administration (FDA) have agreed on the primary endpoint and population for a pivotal Phase 3 study evaluating Edesa's monoclonal antibody candidate, EB05, as a therapy for hospitalized patients with a severe form of respiratory failure.
- Zacks Small Cap Research
EDSA: Positive News Flow to Start 2023…
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Edesa Biotech, Inc. (NASDAQ:EDSA) has started 2023 with multiple positive developments, including positive topline results for the Phase 2b clinical trial of EB01 as a treatment for chronic moderate-to-severe Allergic Contact Dermatitis (ACD), the FDA granting Fast Track designation to EB05, and Health Canada giving approval for a
